



**Office of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

February 10, 2009 6:30 – 9:00 p.m. **

- 1. Executive Session** **6:30 - 7:00**
 - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))
- 2. Introductions and Approval of DUR Board Minutes** **7:00 - 7:05**
(Public Comment Prior to Board Action)
- 3. OVHA Pharmacy Administration Updates** **7:05 - 7:15**
- 4. Medical Director Update** **7:15 - 7:25**
 - Clinical Programs Update
 - Prescriber Comments
- 5. Follow-up Items from Previous Meeting** **7:25 - 7:30**
 - Anti-psychotics: Atypicals and Combinations (Seroquel XR®)
- 6. Clinical Update: Drug Reviews (Abbreviated)** **7:30– 7:45**
(Public comment prior to Board action)
 - Astepro® (azelastine hydrochlorid) Nasal Spray
 - Keppra XR® (levetiracetam extended-release) Tablet
 - Stavzor® (valproic acid delayed release) Capsule
- 7. Review of Newly-Developed/Revised Clinical Coverage Criteria** **7:45 – 7:55**
(Public comment prior to Board action)
 - Urinary Antispasmodics
- 8. Drug Classes – Annual Review** **7:55 – 8:45**
(Public comment prior to Board action)
Class review documents available on OVHA web site 02/10/08 @ 12 Noon
Cardiovascular Agents
 - Coronary Vasodilators/Antianginals
 - Nitrates and Nitrites
 - Ranexa® (ranolazine)
 - Lipotropics
 - Bile Acid Sequestrants
 - Fibric Acid Derivatives
 - Niacin
 - Statins
 - Miscellaneous/Combinations

Gastrointestinal Agents

- Histamine-2 Receptor Antagonists
- Inflammatory Bowel Agents
- Proton Pump Inhibitors: Single/Combo

Anti-emetics

- 5-HT₃s Antagonists
- NK1 Antagonists
- Other

- | | |
|---|--------------------|
| 9. RetroDUR | 8:45 - 8:55 |
| ▪ Provigil® (modafinil) | |
| 10. New Drug Product Plan Exclusions (Consent Agenda Topic) | 8:55 - 8:55 |
| 11. Updated New-to-Market Drug Monitoring Log (Consent Agenda Topic) | 8:55 - 8:55 |
| 12. General Announcements | 8:55 - 9:00 |
| Selected FDA Safety Alerts | |
| ▪ Bisphosphonates - atrial fibrillation | |
| ▪ Topical Anesthetics – adverse effects when applied to large areas | |
| ▪ Plavix® – genetic factors, drug interactions and effect on efficacy | |
| 13. Adjourn | 9:00 |